---
title: Patient Positioning and Airway Management During ERCP
nct_id: NCT02850887
overall_status: COMPLETED
phase: NA
sponsor: Washington University School of Medicine
study_type: INTERVENTIONAL
primary_condition: Airway Management
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02850887.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02850887"
ct_last_update_post_date: 2018-02-06
last_seen_at: "2026-05-12T07:26:05.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Patient Positioning and Airway Management During ERCP

**Official Title:** Patient Positioning and Airway Management During Endoscopic Retrograde Cholangiopancreatography ERCP and the Effect on Airway Complications and Procedure Outcomes in Patients With Risks for Anesthesia Adverse Events

**NCT ID:** [NCT02850887](https://clinicaltrials.gov/study/NCT02850887)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Washington University School of Medicine
- **Conditions:** Airway Management
- **Start Date:** 2016-07-25
- **Completion Date:** 2018-01-04
- **CT.gov Last Update:** 2018-02-06

## Brief Summary

The aim of this study is to determine the effect of airway management (a set of medical procedures performed to prevent airway blockage and thus ensure an open path between a patient's lungs and the atmosphere) during endoscopic retrograde cholangiopancreatography \[(ERCP), a procedure commonly used to treat conditions of the bile ducts and pancreas\] and the effect on airway complications (problems), time to biliary cannulation (access into bile duct) and total procedure duration (length of time). Two methods are being compared and studied: 1) general endotracheal anesthesia: an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose vs 2) deep sedation without endotracheal intubation: local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patient undergoing ERCP without preceding endoscopic ultrasound (EUS)
2. At least one of the following risk factors for adverse events during sedation:

   1. STOP-BANG score of 3 or higher
   2. Abdominal ascites on either physical exam or imaging within the last 14 days
   3. BMI greater than or equal to 35
   4. Chronic lung disease
   5. ASA class 4
   6. Mallampati Class 4 airway (only hard palate visible)
   7. Concurrent moderate to heavy alcohol use (≥4 drinks/day for men and ≥3 drinks/day for women)

Exclusion Criteria:

1. EUS preceding the ERCP
2. Emergent indication for ERCP (eg cholangitis with septic shock)
3. Presence of a tracheostomy
4. Unstable airway
5. Gastric outlet obstruction
6. Altered foregut anatomy (eg Roux-en-Y gastric bypass, Billroth II)
7. Inability to give informed consent
```

## Arms

- **general endotracheal anesthesia** (ACTIVE_COMPARATOR) — an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
- **deep sedation without endotracheal intubation** (ACTIVE_COMPARATOR) — local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.

## Interventions

- **general endotracheal anesthesia** (OTHER) — sedation with the use of endotracheal intubation
- **deep sedation without endotracheal intubation** (OTHER) — deep sedation without endotracheal airway management.

## Primary Outcomes

- **Incidence of sedation related adverse events or the need for airway maneuvers** _(time frame: approximately one year)_

## Secondary Outcomes

- **Procedure duration** _(time frame: intraoperative)_
- **Time to cannulation of intended duct system** _(time frame: during the procedure)_
- **Technical success of ERCP** _(time frame: approximately one year)_
- **Immediate ERCP adverse events** _(time frame: Adverse events within 24 hours of ERCP)_
- **Delayed adverse events** _(time frame: Adverse events occurring within 7 days)_

## Locations (1)

- Washington University School of Medicine in St Louis, St Louis, Missouri, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.washington university school of medicine in st louis|st louis|missouri|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02850887.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02850887*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*